drospirenone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists 968 67392-87-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • drospirenone
  • dihydrospirorenone
  • drospirenona
a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source. It is used in combination with estetrol (nextstellis) as oral contraceptive.
  • Molecular weight: 366.50
  • Formula: C24H30O3
  • CLOGP: 2.84
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 43.37
  • ALOGS: -5.21
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.12 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 76 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
May 19, 2021 EMA Gedeon Richter Plc; Estetra SPRL
May 23, 2019 FDA EXELTIS USA INC
July 23, 2010 PMDA Bayer Yakuhin, Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pregnancy on oral contraceptive 67.17 30.39 12 997 1025 63486988
Pulmonary embolism 39.55 30.39 24 985 116660 63371353
Intermenstrual bleeding 38.35 30.39 11 998 7915 63480098

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pregnancy on oral contraceptive 46.57 35.66 8 820 837 79742723
Pulmonary embolism 40.49 35.66 24 804 171630 79571930

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03AA12 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA18 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AC10 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens
ATC G03FA17 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
PROGESTOGENS AND ESTROGENS IN COMBINATION
Progestogens and estrogens, fixed combinations
FDA CS M0447349 Progesterone Congeners
MeSH PA D004232 Diuretics
MeSH PA D006727 Hormone Antagonists
MeSH PA D000451 Mineralocorticoid Receptor Antagonists
MeSH PA D045283 Natriuretic Agents
FDA EPC N0000175602 Progestin
CHEBI has role CHEBI:49323 contraceptive drugs
CHEBI has role CHEBI:59826 progestins

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Premenstrual dysphoric disorder indication 596004
Contraception indication 13197004
Atrophic vaginitis indication 52441000
Acne vulgaris indication 88616000
Menopausal flushing indication 198436008
Atrophic vulva indication 248861000 DOID:14275
Dysmenorrhea indication 266599000
Controlled ovarian stimulation indication 732970000
Polycystic ovaries off-label use 69878008
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Myocardial infarction contraindication 22298006 DOID:5844
Diplopia contraindication 24982008
Retinal hemorrhage contraindication 28998008
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Acute nephropathy contraindication 58574008
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Uterine leiomyoma contraindication 95315005 DOID:13223
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Endometriosis contraindication 129103003
Bed-ridden contraindication 160685001
Mammography abnormal contraindication 168750009
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Endometrial carcinoma contraindication 254878006 DOID:2871
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Cardiovascular event risk contraindication 395112001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
3MG;14.2MG NEXTSTELLIS MAYNE PHARMA N214154 April 15, 2021 RX TABLET ORAL 7732430 March 2, 2025 USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG BEYAZ BAYER HLTHCARE N022532 Sept. 24, 2010 RX TABLET ORAL 11617751 July 17, 2030 PREVENTION OF PREGNANCY
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG BEYAZ BAYER HLTHCARE N022532 Sept. 24, 2010 RX TABLET ORAL 11617751 July 17, 2030 RAISE FOLATE LEVELS IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION FOR THE PURPOSE OF REDUCING THE RISK OF A NEURAL TUBE DEFECT IN A PREGNANCY
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG BEYAZ BAYER HLTHCARE N022532 Sept. 24, 2010 RX TABLET ORAL 11617751 July 17, 2030 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YEARS OF AGE IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG BEYAZ BAYER HLTHCARE N022532 Sept. 24, 2010 RX TABLET ORAL 11617751 July 17, 2030 TREATMENT OF MOOD CHANGES AND/OR ANXIETY AS SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
3MG,N/A;0.03MG,N/A;0.451MG,0.451MG SAFYRAL BAYER HLTHCARE N022574 Dec. 16, 2010 RX TABLET ORAL 11617751 July 17, 2030 PREVENTION OF PREGNANCY
3MG,N/A;0.03MG,N/A;0.451MG,0.451MG SAFYRAL BAYER HLTHCARE N022574 Dec. 16, 2010 RX TABLET ORAL 11617751 July 17, 2030 RAISE FOLATE LEVELS IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION FOR THE PURPOSE OF REDUCING THE RISK OF A NEURAL TUBE DEFECT IN A PREGNANCY
4MG SLYND EXELTIS USA INC N211367 May 23, 2019 RX TABLET ORAL 10179140 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
4MG SLYND EXELTIS USA INC N211367 May 23, 2019 RX TABLET ORAL 10603281 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
4MG SLYND EXELTIS USA INC N211367 May 23, 2019 RX TABLET ORAL 10849857 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
4MG SLYND EXELTIS USA INC N211367 May 23, 2019 RX TABLET ORAL 11413249 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
4MG SLYND EXELTIS USA INC N211367 May 23, 2019 RX TABLET ORAL 9603860 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
3.5MG DROSPIRENONE EXELTIS USA INC N216285 June 29, 2022 DISCN TABLET, CHEWABLE ORAL 10179140 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
3.5MG DROSPIRENONE EXELTIS USA INC N216285 June 29, 2022 DISCN TABLET, CHEWABLE ORAL 10603281 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
3.5MG DROSPIRENONE EXELTIS USA INC N216285 June 29, 2022 DISCN TABLET, CHEWABLE ORAL 10849857 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
3.5MG DROSPIRENONE EXELTIS USA INC N216285 June 29, 2022 DISCN TABLET, CHEWABLE ORAL 11413249 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
3.5MG DROSPIRENONE EXELTIS USA INC N216285 June 29, 2022 DISCN TABLET, CHEWABLE ORAL 9603860 June 28, 2031 PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
3.5MG DROSPIRENONE EXELTIS USA INC N216285 June 29, 2022 DISCN TABLET, CHEWABLE ORAL June 29, 2025 NEW PRODUCT
3MG;14.2MG NEXTSTELLIS MAYNE PHARMA N214154 April 15, 2021 RX TABLET ORAL April 15, 2026 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mineralocorticoid receptor Nuclear hormone receptor ANTAGONIST IC50 10.50 WOMBAT-PK CHEMBL
Progesterone receptor Nuclear hormone receptor AGONIST EC50 10.50 WOMBAT-PK CHEMBL
Androgen receptor Nuclear hormone receptor IC50 8.50 WOMBAT-PK

External reference:

IDSource
4021271 VUID
N0000179010 NUI
D03917 KEGG_DRUG
4021271 VANDF
C0043822 UMLSCUI
CHEBI:50838 CHEBI
CHEMBL1509 ChEMBL_ID
DB01395 DRUGBANK_ID
C035144 MESH_SUPPLEMENTAL_RECORD_UI
68873 PUBCHEM_CID
2874 IUPHAR_LIGAND_ID
6519 INN_ID
N295J34A25 UNII
11636 RXNORM
16073 MMSL
d04759 MMSL
009133 NDDF
395275003 SNOMEDCT_US
410919000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SLYND HUMAN PRESCRIPTION DRUG LABEL 1 0642-7470 TABLET, FILM COATED 4 mg ORAL NDA 30 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 50419-482 TABLET, FILM COATED 0.25 mg ORAL NDA 28 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 50419-482 TABLET, FILM COATED 0.25 mg ORAL NDA 28 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 50419-482 TABLET, FILM COATED 0.25 mg ORAL NDA 28 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 50419-483 TABLET, FILM COATED 0.50 mg ORAL NDA 28 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 50419-483 TABLET, FILM COATED 0.50 mg ORAL NDA 28 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 50419-483 TABLET, FILM COATED 0.50 mg ORAL NDA 28 sections
Angeliq HUMAN PRESCRIPTION DRUG LABEL 2 54868-6184 TABLET, FILM COATED 0.50 mg ORAL NDA 24 sections